Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $1.26M | $1.84M | $1.18M | $780K | — |
| Revenue growth | — | 46.4% | -36.1% | -33.7% | — |
| Gross profit | -$38.0K | $299K | $287K | $2.00K | — |
| Gross margin | -3.0% | 16.3% | 24.4% | 0.3% | — |
| Operating income | -$5.63M | -$10.1M | -$8.24M | -$4.48M | -$7.90M |
| Operating margin | -448.1% | -548.8% | -701.1% | -573.8% | — |
| Net income | -$8.49M | -$10.1M | -$8.24M | -$5.66M | -$8.88M |
| Net margin | -675.7% | -548.7% | -701.0% | -725.0% | — |
| EPS (diluted) | -$2.43 | -$104.32 | -$176.80 | -$19.68 | — |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | -$5.61M | -$8.92M | -$8.51M | -$5.72M | -$7.00M |
| Capital expenditures | — | $11.0K | $118K | $0.00 | $38.0K |
| Free cash flow | — | -$8.93M | -$8.63M | -$5.72M | -$7.04M |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $13.0M | $3.52M | $3.40M | $2.00M | $12.6M |
| Total assets | $15.0M | $5.88M | $5.16M | $2.81M | $31.6M |
| Total liabilities | $1.76M | $2.25M | $1.58M | $272K | $7.44M |
| Shareholders' equity | $13.3M | $3.63M | $3.58M | $2.54M | $3.31M |
| Retained earnings | -$19.5M | -$29.6M | -$37.9M | -$43.5M | -$52.6M |
| Shares (wtd avg diluted) | 3.49M | 96.8B | 46.6B | 287K | 1.16M |
Every figure is extracted from Valion Bio, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.